Organic Active Ingredients TRIZ Cases

Acyclic CB[n] molecular containers resolve poor drug bioavailability by forming non-covalent complexes that boost solubility up to 2750-fold.

An isoindolin-1-one derivative acts as an allosteric inhibitor to target activated and resistant forms of the EGFR protein.

Combining RAF and MEK inhibitors targets solid tumors with RAS Q61 or G13R mutations, resolving limited treatment effectiveness in NRAS-mutant melanoma.

Heteroaryl substituted aminopyridine compounds inhibit IRAK-4 to treat inflammatory diseases.

Specific heterocyclic substitutions on the pyridine ring enable selective antifungal activity while minimizing mammalian host toxicity.

Quinolone derivatives form irreversible covalent bonds with fibroblast growth factor receptors to inhibit their activity.

Vitamin D glycoside prodrugs activate via tissue enzymes to release active vitamin D locally, preventing systemic hypercalcemia.

Oxetane-substituted compounds enhance aqueous solubility of poorly soluble radioprotectors, resolving precipitation issues while accelerating bone healing.

Substituted bicyclic aza-heterocycles modulate sirtuin proteins to treat aging-related diseases while reducing the side effects of existing therapies.

A bromo-nitrile cyclization process prepares (R)-4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine intermediates.

Segmented molecular design achieves selective ROMK inhibition to treat hypertension while avoiding hypokalemia side effects.

Quinazoline derivatives inhibit DNA methyltransferase to restore tumor suppressor gene expression while improving bioavailability over nucleoside analogues.

Nitrogenous aromatic heterocyclic compounds inhibit ALK5 via palladium-catalyzed coupling reactions.

Orotic acid lowers core body temperature by activating the hepatic urea cycle to reduce metabolic heat production without external instruments.

Merges AKT and WEE1 inhibitors to overcome single-agent resistance in metastatic melanoma while managing side effects through selective pathway targeting.

Cleavable phosphonomethoxy prodrugs enhance brain penetration of gamma-secretase modulators to reduce amyloid beta 42 levels.

SYK agonists bypass defective TREM2 receptors to clear amyloid beta plaques and reverse neuronal damage.

Transforming bimatoprost into a stable crystalline form eliminates precipitation risks, maintaining consistent drug potency for glaucoma treatment.

Thermokinetic compounding creates an amorphous deferasirox dispersion that resolves erratic oral absorption and inconsistent bioavailability.

Combining succulent extracts with alginic acid creates a stable shear-thinning system.

Beta-adrenergic inverse agonists block receptor-mediated mucus hypersecretion, resolving the physiological barrier that causes smoking cessation failure.

Formula I pyrrolidine derivatives serve as mGluR5 antagonists, addressing the lack of specific treatments for chronic pain and memory deficits.

Amine addition salts with amino nicotinic acid derivatives resolve the trade-off between water solubility and hygroscopic instability in DHODH inhibitors.

Converting the compound to a deanol salt resolves contradictions between therapeutic activity and physical stability, ensuring better bioavailability.

Acid hydrolyzed Picrorhiza kurroa extract increases skin thickness and hydration, reducing senile purpuras without irritation.

Novel heterocyclic CGRP receptor antagonists utilize non-oral delivery routes to treat migraine disorders.

Replacing hazardous trimethylaluminum with safer catalysts improves reaction yield while eliminating safety hazards from violent water reactions.

ROR2 inhibitors target the ROR2 pathway to enhance cartilage repair, addressing osteoarthritis progression by suppressing degrading enzymes.

Segmenting the receptor allows cytosolic tail modulators to bypass ectodomain ligand requirements, resolving poor understanding of activation mechanisms.

Removing the amide carbonyl group from SR142948 derivatives improves tumor uptake and expands the therapeutic window for alpha-emitter radioligand therapy.

Amino-functionalized silica stationary phase separates cannabinoids from impurities, achieving high purity yields without complex multi-stage processing.

Specific deutetrabenazine particle sizing balances dissolution profile against product degradation for bioequivalent tablets.

A coalescing filter directs wet gas against a lower endplate to drain liquid, preventing saturation and extending filter life.

Co-administering an antiestrogen with an androgen or aromatase inhibitor elevates testosterone levels in male mammals.

Cannabigerol compounds mitigate seizures without inducing the hypnotic side effects associated with cannabidiol treatments.

Cyano thienotriazolodiazepine compounds bind bromodomain proteins, inhibiting activity while balancing potency and safety profiles.

Segmentation and intermediary linkers improve target specificity while reducing adverse effects on non-target tissues.

6-(1H-imidazo-1-yl)-2-aryl quinazoline derivatives inhibit monoamine oxidase and bind imidazoline receptors to reduce hypertensive crisis risks.

Extracting (24S)-3β-hydroxy-5α-stigmastan-6-one from plumula nelumbinis identifies the active compound that increases NAD+ content and treats type 2 diabetes.

Ambrosia maritima extracts inhibit viral replication and gene expression by targeting the spike protein, main protease, and RNA-dependent RNA polymerase.

Unnatural amino acids introduce specific functional groups to peptides, resolving the trade-off between biological compatibility and functional diversity.

Magnetic nanoparticles transport therapeutic cargo across the blood-brain barrier using external magnetic forces.

6-Methoxybenzoxazolinone downregulates TGF-β/SMAD signaling to reduce liver fibrosis without severe side effects.

Short-chain fructooligosaccharides stimulate offspring growth through gut microbiota modulation.

Pseudoginsenoside RT8 from ginseng seeds inhibits tyrosinase and melanin production, resolving irritation issues found with arbutin.

Depleting guanosine nucleosides with mycophenolic acid while administering melanin creates metabolic barriers against viral replication.

Formula I compounds modulate GPR52 activity, addressing inadequate treatment effectiveness for complex neurological conditions.

Human serum albumin and liposomes protect recombinant epidermal growth factor from denaturation, maintaining biological activity for two years.

Tocopherol-bound nucleic acid complexes cross the blood-brain barrier, enabling antisense effects in the central nervous system.

A prostate medicament combines drone brood with pollen and vitamins to treat adenoma.

Composite formulation reduces oxidative stress from hormonal contraceptives while maintaining high tolerability.

Substituted amino triazoles block AMCase activity, addressing underlying airway remodeling and inflammation in asthma treatment.

3,6-anhydro-L-galactose inhibits oral microorganism growth and acid production.

Periodic iontophoretic doses extend sweat generation duration beyond six hours while maintaining charge density below safe limits.

A spray base material uses a low-molecular gelator to self-assemble into a fibrous network structure.

Substituted pyrrolo-pyridinone compounds inhibit Casein kinase 1 alpha and delta enzymes, addressing the lack of effective drugs for proliferative disorders.

A water-in-oil emulsion disperses ascorbic acid in ultra-fine droplets to mask sour taste.

Novel FLT3 inhibitors target active kinase conformations to overcome clinical resistance in acute myeloid leukemia treatment.

Targeting endoglin limits TGFβ1 signaling and calcineurin expression to reduce fibrosis.

Cyclic pyranopterin monophosphate stabilizes the molybdenum cofactor synthesis pathway to restore neural homeostasis.

Fc-silenced anti-oxMIF antibodies use targeted amino acid substitutions to lower hydrophobicity and aggregation propensity.

Substituted isoindoline compounds inhibit HIV replication by targeting the protein-protein interaction between integrase and LEDGF.

RNA-encoded cytokines activate endogenous immunity to eliminate resistant solid tumors without damaging healthy tissue.

A multichannel microsphere forming unit produces monodisperse biodegradable polymer microspheres via controlled laminar flow through parallel microchannels.

Chromene derivatives inhibit the TCR-Nck interaction in T lymphocytes, resolving toxicity and specificity trade-offs in immunosuppressive therapy.

Antisense oligonucleotides bind to TOMM, TIMM, or APOE isoform polynucleotides to modulate expression and prevent Alu element-induced mitochondrial dysfunction.

Flash column chromatography with reverse phase silica gel separates Sugammadex sodium from impurities.

Selective M3 agonists enhance saliva production without triggering hyperhidrosis side effects.

Cordyceps and shiitake fermentation yields N-acetylglucosamine that restores E-cadherin in liver cancer cells, expanding biological utility beyond nutrition.

Cyclodextrin inclusion complexes boost bioavailability of low solubility APIs while maintaining controlled release profiles.

A topical oral gel combines diclofenac with hyaluronic acid to treat mucosal lesions.

A polypeptide derivative binds to the growth hormone secretagogue receptor to elevate intracellular calcium levels.

Polyarginine-linked GHK tripeptide overcomes hydrophilic cell membrane barriers to deliver skin anti-aging effects at lower concentrations.

Labile bond cleavage releases active immune response modifiers at target sites, reducing systemic toxicity and improving therapeutic index.

Formula III pyrazole compounds modulate MAGL and ABHD6 activity, resolving the lack of effective lipid mediator inhibitors for treating multiple sclerosis.

Disodium EDTA chelates metal ions to stabilize tizanidine liquids, resolving swallowing difficulties and food-dependent absorption delays.

Zinc oxide nanoparticles loaded with linezolid and ceftriaxone treat resistant infections while improving wound healing.

Triethanolamine prevents moxidectin degradation, eliminating restrictive storage conditions.

Hot melt extrusion of tenofovir alafenamide with biodegradable polymer creates sustained release formulations that reduce dosing frequency.

Enantiomerically pure indole compounds modulate aryl hydrocarbon receptor activity to stimulate the immune system.

ZL-n-91 inhibits lung cancer proliferation by targeting PDE4D, avoiding gastrointestinal side effects from non-specific inhibitors.

Polymeric nanoparticles encapsulate lidocaine and prilocaine in a hydrogel matrix to enable rapid topical skin penetration.

Rifaximin reduces bowel toxicity and treatment breaks by targeting bacterial overgrowth, improving cancer therapy tolerance.

Pentaaza-macrocyclic complexes scavenge reactive oxygen species to reduce oxidative stress and inflammation, significantly lowering mucositis severity.

Developing stable ponatinib hydrochloride solvates resolves the trade-off between chemical stability and targeted release profiles.

A curable liquid silicone rubber composition incorporates a silane crosslinking agent to prevent irreversible drug binding and improve API recovery.

Pyridine derivatives inhibit EAAT3 to modulate glutamate levels, addressing limited efficacy in schizophrenia and bipolar disorder treatment.

Thiol-based quenchers neutralize electrophilic pathogen inactivating compounds, reducing unwanted side reactions and adverse immune responses.

Oral inorganic nitrate elevates nitric oxide to treat respiratory distress, replacing invasive procedures with self-administered therapy.